IEVA's Role in Shaping EU Vape Legislation in 2023

Jan.05.2023
IEVA's Role in Shaping EU Vape Legislation in 2023
IEVA aims to influence EU e-cigarette regulations and plans to lower tobacco taxes and ensure diverse flavors are sold.

On January 5th, 2023, 2FIRSTS conducted an interview with Ciprian Boboi, a board member and director of finance and membership for the European E-cigarette Association (IEVA), regarding the organization's plans for growth in 2023 and the future direction of the industry.


As European regulations on the e-cigarette industry become stricter, what role will IEVA play in 2023? Additionally, what are the work plans for IEVA in 2023?


Ciprian Boboi stated that IEVA is the only association capable of influencing EU regulations on electronic cigarettes at the EU level. He also mentioned that IEVA will use its influence in the European electronic cigarette industry and at the EU level to promote the improvement of electronic cigarette legislation across Europe. This legislation will mainly focus on:


The European Union had intended to discuss a taxation policy on tobacco and electronic cigarettes, including efforts to minimize the impact of the tobacco tax on the e-cigarette industry, by December of 2022. However, this plan has been delayed due to a few reasons.


Secondly, it is essential to ensure that disposable electronic cigarettes and a diverse range of flavors can be sold in the European market without any hindrances.


How does IEVA predict the future development direction of the electronic cigarette market? Will disposables continue to dominate?


Ciprian Boboi believes that the introduction of disposable e-cigarettes has fundamentally changed public perception of vaping. Prior to their arrival, few people used e-cigarettes, with many believing they were even more harmful than traditional tobacco products. However, the appearance of disposables quickly made them popular throughout Europe, leading to a recognition that e-cigarettes are a safer alternative. Boboi suggests that disposable e-cigarettes have likely already peaked in terms of popularity, with their market share set to decline. Firstly, some people use disposables to look cool or follow trends, rather than needing nicotine, and will move onto other products like hookah pipes. Secondly, those trying to quit smoking will soon realize that disposables are expensive compared to reusable alternatives like pods or open systems, leading them to switch. Lastly, the popularity of disposables has created numerous environmental problems, with packaging like milk tea cups becoming an attractive purchase for underage users. Therefore, Boboi believes reusable products like pods or open systems will likely become more common in the future.


2FIRSTS: We noticed that IEVA's membership fee is 5000 euros per month, totaling 60,000 euros per year. While this may not be a high cost for tobacco industry giants, it may be a significant expense for many medium and small-sized Chinese businesses. Will IEVA consider adopting a differentiated fee structure in the future?


Ciprian Boboi stated that they have considered this aspect and are willing to negotiate with 2FIRSTS and Chinese e-cigarette companies to develop a customized fee plan that is acceptable for all parties involved. They aim to find a differentiated solution.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei explores staged nicotine pouch delivery, using dynamic membranes to slow early release and gradient particles to sustain later delivery
China Tobacco Hubei Industrial Co., Ltd. disclosed several oral nicotine-related patent applications in August 2026, including two that approach staged nicotine release from different directions. One uses a high-viscosity membrane that forms inside the pouch after contact with saliva to slow rapid early release, while the other uses gradient particles with a faster-disintegrating outer layer and a slower core to create a fast-to-sustained release profile. Together, the filings explore how nicotine pouches could balance initial delivery with release later in use.
Sep.03
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26